EirGenix Inc. Announces 3-Day Stock Option Bidding Ahead of its Late-June IPO
EirGenix Holds Its Pre-IPO Press Conference
EirGenix Signs Trastuzumab Biosimilar License Agreement with Novartis’ Sandoz
EirGenix Awarded for its Innovation at the National Industrial Innovation Awards
EirGenix, Inc. Wins Best Bioprocess Excellence in Taiwan Award
EirGenix, Inc. Officially Opens its New World-Class Commercial Mass Production Facility
EirGenix’s Phase III Clinical Trial of EG12014 Has Enrolled First Patient
2018 Biologics Manufacturing Korea
Cancer Therapeutic Drug EG12014 Is Approved For Phase III Clinical Trial